Department of Surgery, NYU Langone Medical Center/Bellevue Hospital Center, New York, New York.
Department of Surgery, NYU Langone Medical Center/Bellevue Hospital Center, New York, New York.
Surg Obes Relat Dis. 2020 Apr;16(4):503-508. doi: 10.1016/j.soard.2020.01.016. Epub 2020 Jan 23.
We previously conducted a randomized study comparing metabolic surgery with medical weight management in patients with type 2 diabetes (T2D) and body mass index (BMI) 30 to 35 kg/m. At 3-year follow-up, surgery was very effective in T2D remission; furthermore, in the surgical group, those with a higher baseline soluble receptor for advanced glycation end products had a lower postoperative BMI.
To provide long-term follow-up of this initial patient cohort.
University Hospital.
Retrospective chart review was performed of the initial patient cohort. Patients lost to follow-up were systematically contacted to return to clinic for a follow-up visit. Data were compared using 2-sample t test, Fisher's exact test, or analysis of variance when applicable.
Originally, 57 patients with T2D and BMI 30 to 35 kg/m were randomized to metabolic surgery (n = 29) or medical weight management (n = 28). Ten patients in the medical weight management group crossed over to surgery. Five-year follow-up data were available in 43 of 57 (75%) patients. Baseline mean BMI and glycated hemoglobin were 32.6 kg/m and 7.8%, respectively. Median follow-up was 79 and 88 months in the surgical group and nonsurgical group, respectively. Compared with the nonsurgical group, the surgical patients had significantly lower rate of T2D (62% versus 100%; P = .008), lower insulin use (10% versus 50%; P = .0072), lower glycated hemoglobin (6.93% versus 8.26%; P = .012), lower BMI (25.8 versus 28.6 kg/m; P = .007), and higher percent weight loss (21.4% versus 10.3%; P = .025). Baseline soluble receptor for advanced glycation end products was not associated with long-term outcomes.
Metabolic surgery in T2D patients with BMI 30 to 35 kg/m remains effective long term. Baseline soluble receptor for advanced glycation end products are most likely predictive of early outcomes only.
我们之前进行了一项随机研究,比较了代谢手术与 2 型糖尿病(T2D)和身体质量指数(BMI)为 30 至 35kg/m²的患者的医学体重管理。在 3 年随访时,手术在 T2D 缓解方面非常有效;此外,在手术组中,基线可溶性晚期糖基化终产物受体较高的患者术后 BMI 较低。
为初始患者队列提供长期随访。
大学医院。
对初始患者队列进行回顾性病历审查。对失访的患者进行系统联系,以返回诊所进行随访。使用两样本 t 检验、Fisher 确切检验或方差分析比较数据,具体取决于适用情况。
最初,57 名 T2D 且 BMI 为 30 至 35kg/m²的患者被随机分配至代谢手术组(n=29)或医学体重管理组(n=28)。医学体重管理组中有 10 名患者转为手术组。57 名患者中有 43 名(75%)可获得 5 年随访数据。基线平均 BMI 和糖化血红蛋白分别为 32.6kg/m²和 7.8%。手术组和非手术组的中位随访时间分别为 79 个月和 88 个月。与非手术组相比,手术组患者 T2D 发生率显著降低(62%对 100%;P=0.008),胰岛素使用率更低(10%对 50%;P=0.0072),糖化血红蛋白更低(6.93%对 8.26%;P=0.012),BMI 更低(25.8 对 28.6kg/m²;P=0.007),体重减轻百分比更高(21.4%对 10.3%;P=0.025)。基线可溶性晚期糖基化终产物受体与长期结局无关。
代谢手术治疗 BMI 为 30 至 35kg/m²的 T2D 患者长期有效。基线可溶性晚期糖基化终产物受体可能仅预测早期结局。